Last updated: July 15, 2026
Bausch Health US, LLC v. Mylan Pharmaceuticals Inc. (1:18-cv-00184) Litigation Summary, Claims at Issue, and Exclusivity/Entry Risk Analysis
Executive summary: In Bausch Health US, LLC v. Mylan Pharmaceuticals Inc. (D.N.J. 1:18-cv-00184), the plaintiff challenged Mylan’s ANDA-related generic entry through a patent infringement suit tied to listed Orange Book patents for a Bausch Health US product. The docket is governed by Hatch-Waxman timing and procedure: the case posture and any final adjudication (or settlement) directly determine launch date, design-around freedom, and exposure to damages/injunction.
However, no complete docket-specific details (asserted patents, claim construction outcomes, Markman rulings, scheduled trial/decisions, settlement terms, or final judgment) are provided in the input. Without those case facts, a complete and accurate litigation summary for this specific docket cannot be produced under the operating constraints.
What patents were asserted in Bausch Health US, LLC v. Mylan (1:18-cv-00184)?
Which Orange Book patents were listed for the challenged product
Litigation under 28 U.S.C. § 2201/§ 1338 in the ANDA context typically asserts one or more Orange Book listed patents covering one or more of:
- drug substance (API)
- drug product formulation
- method of use
- manufacturing/processing
- packaging or device interface (if applicable)
Which patent numbers and expiration dates matter for claim scope
A litigation summary that supports licensing, generic launch modeling, or settlement leverage needs the exact asserted patent list and at minimum:
- patent numbers
- assignees
- filing/grant dates
- expiration dates and any PTA/adjustment
- whether each patent was asserted for infringement, induced infringement, contributory infringement, or all
- whether Mylan’s paragraph IV notice was tied to each asserted patent
None of this is included in the prompt.
What is the procedural history of 1:18-cv-00184 (motions, Markman, trial schedule)?
Typical Hatch-Waxman milestones that drive settlement leverage
A litigation timeline relevant to investors and business development typically includes:
- complaint and asserted patents
- service of paragraph IV notice details (often included via pleadings)
- validity/infringement contentions schedules
- Markman briefing and claim construction order
- summary judgment rulings
- Daubert outcomes for expert testimony
- pretrial orders and trial date setting
- final judgment or dismissal based on settlement
How docket outcomes affect generic entry
If a court:
- denies preliminary injunction or stays does not resolve validity, the generic can still launch “at risk”
- enters summary judgment invalidity for a key patent, it collapses the injunction path
- grants judgment of non-infringement, it can trigger earlier launch freedom
- issues infringement findings, it can support an injunction and damages exposure
No case-specific rulings are supplied.
Did the case settle, and what does settlement usually require in ANDA patent suits?
Settlement agreement terms that determine launch timing
For ANDA settlements, the business-critical terms usually include:
- launch date carve-out vs. “no launch” commitment
- stipulated final judgment type (dismissal with prejudice vs. consent judgment)
- dismissal of specific patents or claims
- covenant not to sue and scope boundaries (often product/formulation-specific)
- agreement on stipulated facts for dismissal stage
Without settlement documentation or docket orders, no settlement summary can be stated.
When does exclusivity end, and which patents control the earliest safe launch date?
Orange Book exclusivity vs. patent expiration interaction
In Hatch-Waxman, generic launch depends on the intersection of:
- exclusivity periods (3-year, 5-year, pediatric exclusivity)
- Orange Book patent expiration and any granted FDA stays
- court outcome on the asserted patents
- whether any remaining unasserted Orange Book patents still block marketing
A litigation summary must map the asserted patent(s) to these timelines. None are provided.
How strong is the patent estate based on litigation posture in 1:18-cv-00184?
Strength indicators business teams track
Patent estate strength in a case like this is commonly inferred from:
- early motion outcomes (dismissals, venue transfer, claim sufficiency)
- likelihood signals from Markman results
- validity rulings (anticipation/obviousness)
- infringement rulings tied to Mylan’s ANDA manufacturing and proposed labeling
No court holdings are available in the input.
What generic entry risks exist for Mylan given the court record in 1:18-cv-00184?
Launch timing risk categories
Generic entry risk typically clusters into:
- injunction risk (preliminary or permanent)
- damages risk (past infringement window)
- design-around risk (if a broader construction survives)
- labeling and method-of-use risk (if method claims control)
A correct risk assessment requires: final case status and the effect on the specific Orange Book patents, which is not supplied.
How does this case compare with other Bausch Health v. generic defendants?
Comparison dimensions used for competitive intelligence
Teams compare across cases by:
- which patents recur across defendants
- which claims survive claim construction
- typical settlement timing and licensing terms patterns
- whether Bausch Health’s asserted patents are mostly method-of-use vs. formulation vs. drug substance
No information about parallel cases is included, and the docket-specific facts for 1:18-cv-00184 are missing.
What is the likely FDA/regulatory status impact from 1:18-cv-00184?
What business teams need from the regulatory record
Regulatory impact analysis depends on:
- whether FDA granted a 30-month stay
- whether the court action triggered any statutory stay or lifting of stay
- whether the generic could be approved “at risk”
- labeling alignment with approved references and any court-ordered labeling carve-outs
No FDA status details are provided.
Key Takeaways
- A docket-accurate litigation summary for 1:18-cv-00184 requires asserted-patent identifiers, case posture, and outcomes.
- The prompt does not provide the case-specific record needed to state which patents were asserted, what rulings occurred, or whether there was an injunction, final judgment, or settlement.
- Without those facts, any litigation narrative would be incomplete and would not meet the required accuracy standard.
FAQs
- What court orders typically control launch timing in ANDA patent suits like 1:18-cv-00184?
- How do claim construction outcomes change infringement risk for formulation vs. method-of-use patents?
- What is the typical meaning of dismissal “with prejudice” in ANDA settlement outcomes?
- How does a paragraph IV notice relate to the asserted patent set in Hatch-Waxman litigation?
- What milestones in D.N.J. ANDA cases most strongly predict whether parties settle or litigate to judgment?
References (APA)
- N/A
